AMRN vs. GBIO, HRTX, YMAB, AUPH, PCRX, BLTE, KNSA, SYRE, MNKD, and ANIP
Should you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Generation Bio (GBIO), Heron Therapeutics (HRTX), Y-mAbs Therapeutics (YMAB), Aurinia Pharmaceuticals (AUPH), Pacira BioSciences (PCRX), Belite Bio (BLTE), Kiniksa Pharmaceuticals (KNSA), Spyre Therapeutics (SYRE), MannKind (MNKD), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical preparations" industry.
Amarin (NASDAQ:AMRN) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings.
Amarin has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.87, meaning that its stock price is 187% more volatile than the S&P 500.
In the previous week, Amarin had 1 more articles in the media than Generation Bio. MarketBeat recorded 3 mentions for Amarin and 2 mentions for Generation Bio. Generation Bio's average media sentiment score of 1.52 beat Amarin's score of 1.01 indicating that Generation Bio is being referred to more favorably in the news media.
Amarin has higher revenue and earnings than Generation Bio. Amarin is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
Amarin has a net margin of -18.96% compared to Generation Bio's net margin of -1,696.87%. Amarin's return on equity of -9.48% beat Generation Bio's return on equity.
22.3% of Amarin shares are held by institutional investors. Comparatively, 95.2% of Generation Bio shares are held by institutional investors. 2.0% of Amarin shares are held by company insiders. Comparatively, 21.1% of Generation Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Amarin currently has a consensus target price of $1.08, indicating a potential upside of 25.24%. Generation Bio has a consensus target price of $8.00, indicating a potential upside of 151.57%. Given Generation Bio's stronger consensus rating and higher probable upside, analysts clearly believe Generation Bio is more favorable than Amarin.
Amarin received 804 more outperform votes than Generation Bio when rated by MarketBeat users. Likewise, 74.45% of users gave Amarin an outperform vote while only 67.86% of users gave Generation Bio an outperform vote.
Summary
Amarin and Generation Bio tied by winning 9 of the 18 factors compared between the two stocks.
Get Amarin News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
